Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Harrow Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HROW
Nasdaq
2834
https://www.harrow.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Harrow Inc
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
- Apr 25th, 2024 11:00 am
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
- Apr 2nd, 2024 12:16 pm
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript
- Mar 21st, 2024 1:55 pm
Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023
- Mar 19th, 2024 10:51 pm
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
- Mar 19th, 2024 9:45 pm
Harrow (HROW) Fell on Lowering the Guidance
- Mar 13th, 2024 10:35 am
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
- Mar 5th, 2024 12:00 pm
Here’s How Harrow (HROW) Weighed on SRK Capital’s Performance
- Feb 21st, 2024 11:47 am
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
- Feb 15th, 2024 9:01 pm
Harrow Announces New Appointments to its Board of Directors
- Jan 29th, 2024 12:00 pm
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
- Jan 11th, 2024 12:00 pm
Melt Pharmaceuticals Provides Corporate Update
- Jan 3rd, 2024 12:15 pm
Harrow Partners with Leading Healthcare Market Access Technology Platforms
- Jan 3rd, 2024 12:00 pm
7 Short-Squeeze Stocks That Are Screaming for Speculation
- Dec 24th, 2023 6:08 pm
Harrow Completes Transfer of the TRIESENCE® New Drug Application
- Nov 29th, 2023 12:00 pm
Harrow to Present at Two Investor Conferences in November
- Nov 20th, 2023 12:00 pm
Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 5:56 pm
Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023
- Nov 13th, 2023 10:07 pm
Harrow Announces Third Quarter 2023 Financial Results
- Nov 13th, 2023 9:01 pm
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
- Oct 30th, 2023 12:00 pm
Scroll